USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Acenta Discovery, Inc.
City: Tucson
State: AZ
Zip+4: 85747
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (520) 799-7304

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $1,990,168.00 4

Award List:

NET - Selective Ligands for the Treatment of Depression

Award Year / Program / Phase: 2003 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
Principal Investigator: Kenneth M. Johnson
Award Amount: $545,039.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is expected that depression may be the second most serious medical condition with respect to global… More

Akt Inhibitors to Treat Ewing's Sarcoma

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: GEORGETOWN UNIVERSITY
Principal Investigator: Jeffrey A. Toretsky
Award Amount: $596,620.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab of the Lombardi Cancer Center to create and preclinically evaluate novel inhibitors of the protein… More

Caspase Inhibitor for Neuroprotection

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: GEORGETOWN UNIVERSITY
Principal Investigator: Alexander G. Yakovlev
Award Amount: $348,523.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuronal loss during normal development, after acute neuronal injury, and in chronic degenerative… More

Development of NET-Selective Piperidine-Based PET Ligand

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: MASSACHUSETTS GENERAL HOSPITAL
Principal Investigator: Annaliisa Brownell
Award Amount: $499,986.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as depression. The economic burden of depression alone is immense. Of the $83.1 billion spent in 2000 on… More